Unconfigured Ad
Collapse
Discussion of next-gen sequencing related bioinformatics: resources, algorithms, open source efforts, etc
| Forums | Topics | Posts | Last Post |
|---|
No forums found.
There are no conversations in this channel.
Please log in to your account to view your subscribed posts.
| Topics | Statistics | Last Post | ||
|---|---|---|---|---|
|
Started by laura, 05-09-2011, 04:42 AM
|
35 responses
107,615 views
0 reactions
|
Last Post
by laura
12-05-2013, 02:37 AM
|
||
|
Started by sci_guy, 01-23-2008, 11:19 PM
|
236 responses
684,148 views
1 reaction
|
Last Post
by ECO
12-25-2009, 06:45 PM
|
||
|
Started by Alirez, 04-18-2016, 02:54 PM
|
1 response
3,733 views
0 reactions
|
Last Post
by Alirez
04-19-2016, 05:02 AM
|
||
|
Started by biolid, 04-19-2016, 02:28 AM
|
0 responses
1,463 views
0 reactions
|
Last Post
by biolid
04-19-2016, 02:28 AM
|
||
|
Started by Abdulaziz, 04-18-2016, 10:01 PM
|
3 responses
2,161 views
0 reactions
|
Last Post
by lindenb
04-19-2016, 02:24 AM
|
||
|
Started by epi, 04-18-2016, 07:07 AM
|
1 response
1,305 views
0 reactions
|
Last Post
by lindenb
04-18-2016, 08:34 AM
|
||
|
Started by Areeya, 04-18-2016, 12:44 AM
|
1 response
1,352 views
0 reactions
|
Last Post
by westerman
04-18-2016, 08:34 AM
|
||
|
Started by user 31888, 04-15-2016, 05:25 PM
|
1 response
2,333 views
0 reactions
|
Last Post
by Jessica_L
04-18-2016, 07:09 AM
|
||
|
Started by Reinator, 04-15-2016, 11:17 AM
|
4 responses
7,040 views
0 reactions
|
Last Post
by GenoMax
04-18-2016, 06:44 AM
|
||
|
Started by Jsmith41, 04-17-2016, 02:20 PM
|
1 response
1,393 views
0 reactions
|
Last Post
by rory
04-18-2016, 06:32 AM
|
||
|
Started by Lien, 04-18-2016, 01:09 AM
|
1 response
1,299 views
0 reactions
|
Last Post
by GenoMax
04-18-2016, 02:58 AM
|
||
|
Started by geertvandeweyer, 04-18-2016, 02:12 AM
|
0 responses
2,447 views
0 reactions
|
Last Post
|
No topics found.
-
Page of 0
-
Filter
widgetinstance 229 (Webinars) skipped due to lack of content & hide_module_if_empty option.
Recent Articles
Collapse
-
by SEQadmin2
Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.
The systematic characterization of the human proteome has...-
Channel: Articles
07-20-2026, 11:48 AM -
-
by SEQadmin2
Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
...-
Channel: Articles
07-09-2026, 11:10 AM -
-
by SEQadmin2
Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.
There is no single reason why many patients don’t respond to treatment as expected. Cancer is...-
Channel: Articles
07-08-2026, 05:17 AM -
ad_right_rmr
Collapse
News
Collapse
| Topics | Statistics | Last Post | ||
|---|---|---|---|---|
|
Started by SEQadmin2, Today, 12:17 PM
|
0 responses
10 views
0 reactions
|
Last Post
by SEQadmin2
Today, 12:17 PM
|
||
|
Started by SEQadmin2, Yesterday, 11:41 AM
|
0 responses
11 views
0 reactions
|
Last Post
by SEQadmin2
Yesterday, 11:41 AM
|
||
|
Started by SEQadmin2, 07-20-2026, 11:10 AM
|
0 responses
23 views
0 reactions
|
Last Post
by SEQadmin2
07-20-2026, 11:10 AM
|